Burning Rock Biotech Limited (NASDAQ:BNR - Get Free Report) shares were down 13.4% during mid-day trading on Monday . The stock traded as low as $4.90 and last traded at $4.90. Approximately 7,883 shares traded hands during mid-day trading, a decline of 43% from the average daily volume of 13,817 shares. The stock had previously closed at $5.66.
Burning Rock Biotech Price Performance
The company's 50-day moving average is $6.60 and its 200-day moving average is $5.27. The firm has a market capitalization of $50.20 million, a price-to-earnings ratio of -1.63 and a beta of 0.55.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Burning Rock Biotech stock. Citadel Advisors LLC bought a new stake in Burning Rock Biotech Limited (NASDAQ:BNR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 12,267 shares of the company's stock, valued at approximately $83,000. Citadel Advisors LLC owned approximately 0.12% of Burning Rock Biotech as of its most recent filing with the SEC. 30.03% of the stock is owned by hedge funds and other institutional investors.
About Burning Rock Biotech
(
Get Free Report)
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Burning Rock Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Burning Rock Biotech wasn't on the list.
While Burning Rock Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
